Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity
- Status
- COMPLETED
- Phase
- PHASE4
Clinical Trials Related to Ipsen
Related studies linked through entity extraction aliases.
Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq
- Status
- COMPLETED
- Phase
- PHASE3
A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide
- Status
- COMPLETED
- Phase
- N/A
Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm
- Status
- COMPLETED
- Phase
- PHASE2
Effects on Quality of Life Following Dysport Treatment in Post-stroke Spasticity of the Arm
- Status
- COMPLETED
- Phase
- PHASE4
Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
- Status
- COMPLETED
- Phase
- PHASE4
Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis
- Status
- COMPLETED
- Phase
- PHASE3
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
- Status
- COMPLETED
- Phase
- PHASE3
Efficacy Study of Dysport® in the Treatment of Anal Fissure.
- Status
- COMPLETED
- Phase
- PHASE2
Post Marketing Surveillance Study of Dysport
- Status
- COMPLETED
- Phase
- N/A
Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment in Patients With Primary Myofascial Pain Syndrome
- Status
- COMPLETED
- Phase
- PHASE2
Somatuline Autogel: Acromegaly Self/Partner Injection Study
- Status
- COMPLETED
- Phase
- PHASE4
Study to Assess the Efficacy and Safety of Dysport® in Upper Back Myofascial Pain Syndrome
- Status
- COMPLETED
- Phase
- PHASE2
Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency
- Status
- COMPLETED
- Phase
- PHASE3
Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
- Status
- TERMINATED
- Phase
- PHASE3
Diflomotecan (BN80915) Administered Once Every 3 Weeks in Treating Patients With Sensitive Small Cell Lung Cancer (SCLC)
- Status
- COMPLETED
- Phase
- PHASE2